Clinical Outcomes for Patients With t(4;11)(q21;q23)
| Proportion With t(4;11)(q21;q23) . | UKALL XA Adults . | TIWCL Adults . | TIWCL Children . |
|---|---|---|---|
| 10/350 . | 9/172 . | 9/157 . | |
| CR (%) | 70 | 50 | 88 |
| MCRD (mo) | NA | NA | 3 |
| MST (mo) | NA | 7 | 9 |
| MDFS (mo) | 4 | 2 | 5 |
| DFS | 24% at 3 yr | 0% at 5 yr | 0% at 5 yr |
| Proportion With t(4;11)(q21;q23) . | UKALL XA Adults . | TIWCL Adults . | TIWCL Children . |
|---|---|---|---|
| 10/350 . | 9/172 . | 9/157 . | |
| CR (%) | 70 | 50 | 88 |
| MCRD (mo) | NA | NA | 3 |
| MST (mo) | NA | 7 | 9 |
| MDFS (mo) | 4 | 2 | 5 |
| DFS | 24% at 3 yr | 0% at 5 yr | 0% at 5 yr |
Abbreviations: MCRD, median complete remission duration; MDFS, median disease-free survival.
Data from the UKALL XA trial,10 the Third International Workshop on Chromosomes in Leukemia (TIWCL),37 and Bloomfield et al.18